CN57 - Proposals for implementation of a multidimensional platform for the advancement of oncology nursing in Latin America (The INCREASE proposal)

Background

Cancer cases and deaths are projected to increase. Prioritizing nursing research collaboration can help combat this—the INCREASE Proposal aimed to facilitate interdisciplinary dialogue and improve oncology nursing in LATAM.

Methods

At CTIC, experts from different sectors were organized into working groups to address and resolve four challenges faced by oncology nurses in Colombia.

Results

Improving Oncology Nursing Education: Insufficient education and limited knowledge and skills have been identified. To address this, national postgraduate training consolidation, promotion of Advanced Practice in oncology nursing, and partnerships between healthcare providers and academia have been proposed. Mapping the Pathway to Oncology Nursing Research: Limited funding, absence of formal roles, insufficient academic training, and time constraints are obstacles. Empowering nurses as principal investigators and promoting collaboration among academia, healthcare providers, and the community is proposed. Matching oncology nursing and navigation models to healthcare system: Data management and decision-making are difficult in developing oncology nursing care models. Recommendations include integrating advanced technologies, training nurses in IT, creating experience-sharing networks, involving patients and families in support networks, and expanding the patient navigator role. Encouraging the implementation of evidence-based clinical guidelines to standardize nursing practices: Minimal nursing involvement, insufficient institutional support, high innovation costs, language barriers, and informal knowledge exchange were identified. Academic training methodologies, institutional policies, tracking results, and academic programs for students are proposed.

Conclusions

The four groups proposed solutions that included improving nurses' knowledge and competencies, increasing training programs, and recognizing their expertise. The groups recommended collaborating with the government, revising salaries, promoting academic research, and standardizing optimal working conditions.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

J.A. Zuluaga: Financial Interests, Personal, Speaker’s Bureau: BMS, AstraZeneca; Financial Interests, Personal, Expert Testimony: AstraZeneca; Financial Interests, Personal, Leadership Role: AstraZeneca; Financial Interests, Personal, Product Samples: AstraZeneca, Roche, Pfizer. L. Gutiérrez-Babativa: Financial Interests, Personal, Speaker, Consultant, Advisor: Janssen, BMS. A.F. Cardona Zorrilla: Financial Interests, Personal, Invited Speaker, Immunotherapy in lung cancer, ALK/EGFR targeted therapy, biomarkers: Roche; Financial Interests, Personal, Invited Speaker, EGFR targeted therapy, NSCLC biomarkers: Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker, EGFR/ALK targeted therapy: Pfizer; Financial Interests, Personal, Invited Speaker, NSCLC biomarkers: Novartis; Financial Interests, Personal, Invited Speaker, EGFR targeted therapy, locally advanced NSCLC immunotherapy, NSCLC biomarkers: AstraZeneca; Financial Interests, Personal, Advisory Board, KRAS targeted therapy and genomic testing: Amgen; Financial Interests, Personal, Advisory Board, NSCLC immunotherapy, melanoma biomarkers: BMS; Financial Interests, Personal, Advisory Board, Genomic tumor board implementation, NSCLC biomarkers: Foundation Medicine; Financial Interests, Personal, Advisory Board, NSCLC immunotherapy, MET targeted therapy: Merck Serono; Financial Interests, Personal, Advisory Board, NSCLC immunotherapy and molecular testing: MSD; Financial Interests, Personal, Advisory Board, EGFR/EGFRvIII directed therapy: Abbie; Financial Interests, Personal, Advisory Board, EGFR targeted therapy: Janssen; Financial Interests, Personal, Member of Board of Directors: Foundation for Clinical and Applied Cancer Research - FICMAC; Financial Interests, Personal, Full or part-time Employment, Head of Research, Science and Education - Patent process: Foundation CTIC; Financial Interests, Personal, Steering Committee Member: Roche; Financial Interests, Personal, Coordinating PI: AstraZeneca; Financial Interests, Personal, Local PI: MSD, Roche, BMS; Financial Interests, Institutional, Research Grant: Roche, AstraZeneca, Foundation Medicine. All other authors have declared no conflicts of interest.